Preventing perinatal transmission of HIV-1 infection.

It is now known that with the use of antiretroviral prophylaxis with zidovudine, elective caesarean section delivery and refraining from breastfeeding the rate of mother-child transmission of HIV infection can be reduced to less than 2%.

[1]  M. Newell.  Breastfeeding and HIV infection: a global perspective. , 1999, Hospital medicine.

[2]  P. Rustin,et al.  Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues , 1999, The Lancet.

[3]  Dorothy Bray,et al.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial , 1999, The Lancet.

[4]  H. Coovadia,et al.  Randomized trial testing the effect of vitamin A supplementation on pregnancy outcomes and early mother-to-child HIV-1 transmission in Durban, South Africa. South African Vitamin A Study Group. , 1999, AIDS.

[5]  R. Tarone,et al.  Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. , 1999, AIDS.

[6]  J. Read,et al.  The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies: the International Perinatal HIV Group , 1999 .

[7]  M. Newell,et al.  British HIV Association guidelines for prescribing antiretroviral therapy in pregnancy (1998). , 1999, Sexually transmitted infections.

[8]  F. Parazzini.  Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial , 1999, The Lancet.

[9]  R. Salamon,et al.  6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial , 1999, The Lancet.

[10]  J. Karon,et al.  Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial , 1999, The Lancet.

[11]  S. Gortmaker,et al.  Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. , 1999, JAMA.

[12]  M. Newell,et al.  Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. The European Collaborative Study. , 1999, AIDS.

[13]  B. Hirschel,et al.  Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects , 1998, AIDS.

[14]  J. Tesoriero,et al.  Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. , 1998, The New England journal of medicine.

[15]  R. Sperling,et al.  Safety of the maternal–infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study , 1998, AIDS.

[16]  A. Berrebi,et al.  Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. , 1998, JAMA.

[17]  G. Pardi,et al.  Therapeutic and other interventions to reduce the risk of mother‐to‐child transmission of HIV‐1 in Europe , 1998, British journal of obstetrics and gynaecology.

[18]  J. Kaldor,et al.  Time trends in HIV infection among pregnant women in Europe , 1998, AIDS.

[19]  R. Biggar,et al.  Effect of cleansing the birth canal with antiseptic solution on maternal and newborn morbidity and mortality in malawi: clinical trial , 1997, BMJ.

[20]  R. Gelber,et al.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.